LianBio (LIANY)
OTCMKTS · Delayed Price · Currency is USD
0.0570
+0.0040 (7.55%)
Jul 31, 2025, 3:46 PM EDT

LianBio Company Description

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries.

The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn’s disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus.

It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy.

The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

LianBio
CountryCayman Islands
Founded2019
IndustryBiotechnology
SectorHealthcare
Employees163
CEOAdam Stone

Contact Details

Address:
103 Carnegie Center Drive
Princeton, 08540
United States
Phone609 486 2308
Websitelianbio.com

Stock Details

Ticker SymbolLIANY
ExchangeOTCMKTS
Fiscal YearJanuary - December
Reporting CurrencyUSD
ISIN NumberUS53000N1081
SIC Code2836

Key Executives

NamePosition
Adam Leo StoneInterim Chief Executive Officer and Director
Konstantin PoukalovFounder and Executive Chairman
Ehong GuInterim Chief Financial Officer, Vice President and Head of Global Finance
Ji ChenSenior Vice President and General Counsel
Brianne JahnChief Business Officer
Levvy Lv D. EngSenior Vice President and Global Head of Development